Study of the Sars-Cov2 Neuroinvasiveness - COVID19
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia,
ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological
complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and
cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can
be safely removed from the patient. In this study, COVID-19 patients will be evaluated first,
for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the
consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.